Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.
Approval Alert | Perioperative Nivolumab/Chemotherapy in Resectable NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma Trials You May Have Missed at ASCO 2026
2
Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC
3
Daraxonrasib/Vopimetostat Yield Stunning Response Rate in MTAP-del Pancreatic Cancer
4
77 Updated Efficacy of Mutant-Selective PI3Kα Inhibitor Zovegalisib (RLY-2608) in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial
5